Chordoid Meningioma: a Retrospective Study of 17 Cases at a Single Institution
Zhu Hong-da,Chen Hong,Xie Qing,Gong Ye,Mao Ying,Zhong Ping,Che Xiao-ming,Jiang Chen-chuan,Huang Feng-ping,Zheng Kang,Li Shi-qi,Gu Yu-xiang,Bao Wei-ming,Yang Bo-jie,Wu Jin-song,Wang Yin,Xie Li-qian,Zheng Ming-zhe,Tang Hai-liang,Wang Dai-jun,Chen Xian-cheng,Zhou Liang-fu
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20122880
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:Chordoid meningioma (CM), characterized by its resemblance to chordoma, was first described by Kepes et al1 in 1988, and classified histologically as a WHO grade II neoplasm in the 2000 revision of the WHO grading system, featured by its aggressive clinical course, great risk of recurrence, and infrequent association with hematological conditions.2 This article describes the clinical course, radiological characteristics, postoperative treatment, and prognosis of 17 patients with CM who underwent surgical treatment at our hospital. METHODS Seventeen patients were diagnosed with CM at Shanghai Huashan Hospital of Fudan University, Shanghai, China, from 2005 to 2010. This cohort constituted 0.32% (17/5298) of all meningioma cases diagnosed during the study period. The patients were eight males and nine females aged 14 to 74 years (mean, (50.9±13.5) years). Written informed consent was obtained from patients in compliance with the Human Subjects Institutional Review Boards of Huashan Hospital. Clinical information was retrieved from the medical records, including initial symptoms, surgical findings, complementary treatments, and outcomes. All diagnoses were reviewed and confirmed by Dr. CHEN Hong, a senior neuropathologist in the Department of Neuropathology at the hospital. Specimens from all patients were stained with periodic acid-Schiff with and without diastase, mucicarmine, and alcian blue at pH 2.5. Immunohistochemical staining was performed using monoclonal antibodies to epithelial membrane antigen, vimentin, glial fibrillary acidic protein, S-100, and Molecular Immunology Borstel number 1 antibody (MIB-1). All antibodies were obtained from M/S Dako Patts, Denmark. Three of the 17 patients (17.6%) were lost to follow-up after surgery. The remaining 14 patients were followed up for a median of 40.8 months (range, 12-69 months) by direct patient contact or by telephone. Follow-up was recorded to December 25, 2011. RESULTS Six patients presented with headaches and four patients presented with visual disturbance, hemiparesis, and epilepsy. Other symptoms included dizziness, vomiting, ataxia, decreased level of consciousness, facial numbness, and slurred speech. Two cases were asymptomatic, and their tumors were found incidentally on computed tomography or magnetic resonance imaging (MRI). One patient had a 20-year history of visual loss. The remaining 14 patients had a mean duration of symptoms of 4.6 months. One 17-year-old patient and two adult patients had microcytic hypochromic anemia at the time of presentation (cases 9-11) (Table 1).Table 1: . Cases of chordoid meningioma in our hospital (2005-2010)MRI data were available for 15 patients. Tumor diameter ranged from 20 to 80 mm. Most lesions were hypointense or isointense on T1-weighted images and hyperintense on T2-weighted images, and showed homogenous enhancement after administration of gadolinium with a “dural tail”. These lesions had been correctly diagnosed as meningiomas, but not the chordoid type. Four cases (cases 6 and 9-11) had atypical findings on MRI (heterogeneous enhancement, bone invasion, peritumoral edema, cystic change, or necrosis) or an atypical clinical presentation and were initially diagnosed as glioma (n=2) or trigeminal neurinoma (n=2). The locations of tumors were not exceptional compared with the usual type of meningioma. The majority of tumors (82.4%) were supratentorial; tumors were located at the convexity (n=7), middle skull base (n=5), clivus (n=2), anterior skull base (n=1), cerebellopontine angle (n=1), and corpus callosum (n=1). Aggressive appearance and peritumoral edema were observed in seven (41.2%) and nine (52.9%) cases, respectively. At operation, most tumors were large and well circumscribed. Bone invasion was present in many cases. Fifteen patients underwent gross total tumor resection (Simpson grade I or II). In the remaining two cases (cases 6 and 12), complete resection was not possible because of high vascularity or extensive tumor burden, and these patients underwent subtotal resection (Simpson grade III or IV). The specimens were stained with hematoxylin and eosin according to standard protocol. The tumor cells were histologically similar to chordoma, with abundant clear cytoplasm and distinct cellular outlines, some exhibiting cytoplasmic vacuolization and forming cords in abundant mucoid matrix background. Immunohistochemical staining was positive for epithelial membrane antigen and vimentin in all cases. Staining for glial fibrillary acidic protein was negative in all cases. Periodic acid-Schiff staining was positive in all cases and S-100 staining was partially positive in four cases. Lymphocytic inflammation was present in the majority of tumors. The MIB-1 index ranged from <1% to 10% (median, 2%). Follow-up was recorded until December 25, 2011. The mean follow-up period was 40.8 months (range, 12-69 months). One patient (case 1) died of disease immediately after surgery. One patient (case 4) who initially underwent gross total resection but did not receive postoperative adjuvant therapy developed local recurrence at 31 months after surgery. Five patients received postoperative radiotherapy (three received fractionated stereotactic radiosurgery and two received gamma knife therapy), and follow-up MRI showed no recurrence or progression. Two of these patients who underwent subtotal resection and fractionated stereotactic radiosurgery were alive and well with residual tumor at the time of the last follow-up. No cases of cerebrospinal fluid seeding or extracranial metastasis were observed. DISCUSSION Since CM was first described by Kepes et al1 in 1988, our understanding of this tumor has increased greatly. Initially the tumor was thought to occur mostly in young individuals, and to be commonly associated with Castleman syndrome (CS).3 More recently, it has been found to occur at all ages and occasionally be associated with CS. The estimated incidence is nearly 0.5%-1.0% of surgically removed meningiomas.4,5 Our findings are similar, with the 17 cases in our series accounting for 0.32% (17/5298) of the meningioma patients treated at our hospital. The most common symptom at presentation was headache (6/17). Other symptoms varied depending on tumor localization and size, with no specific clinical manifestations observed. CS is an atypical lymphoproliferative disorder first described by Benjamin Castleman in mediastinal lymph nodes in 1956.3 Systemic forms are characterized by multiple organ dysfunction, generalized adenopathy, fever, and hypergammaglobulinemia. Kepes et al1 reported seven younger patients who had CM associated with some features of CS. Among them, two patients had anemia that immediately diminished after surgery and reappeared with local tumor recurrence. However, Couce et al4 reviewed 42 cases of CM mostly among adults (mean age of 47.4 years), and reported that none of them showed anemia and/or dysgammaglobulinemia. In our study, three patients (17.6%; one 17-year-old and two adults) (Table 1) had microcytic hypochromic anemia at the time of presentation, but no other features of CS were observed. This confirms that CM is not always associated with CS and is not limited to children. Given the rarity and variable presentation of CM, accurate preoperative diagnosis is very difficult. In this series, most lesions (76.5%) had typical characteristics of meningioma on MRI, and had been correctly diagnosed as meningioma, although not of the chordoid type. Four cases with atypical MRI findings (heterogeneous enhancement, bone invasion, peritumoral edema, cystic change, or necrosis) or an atypical clinical presentation were initially diagnosed as glioma or trigeminal neurinoma. Although distinguishing CM on radiological findings alone seems impossible, CM should be considered when patients present with the clinical characteristics described in our patients. Some components of CS, such as microcytic anemia or elevated ESR, can be used to facilitate the preoperative diagnosis, especially in younger patients. However, definitive diagnosis of CM can only be made by accurate histopathological examination. The extent of resection is generally regarded to be one of the most important prognostic factors in patients with meningioma. The recurrence rate after subtotal resection of CM is high.4 However, complete resection is not always possible in cases with extensive tumor burden or tumors in close proximity to major blood vessels or important functional areas of the brain. Couce et al4 reported a series of 42 patients with CM who had a 39% recurrence rate at 1.8 to 16 years after surgery (mean, 5.6 years). Thirteen of the 14 cases with recurrence underwent subtotal resection, suggesting that subtotal resection increases the likelihood of recurrence. In our series, excluding the patient who died immediately after surgery, one patient developed recurrence (6.3%, case 4) after 31 months. This patient underwent gross total resection but did not receive postoperative adjuvant therapy. In contrast, five patients who received postoperative radiotherapy (fractionated stereotactic radiosurgery in three patients and gamma knife therapy in two patients) showed no recurrence or progression on MRI. Two of these patients who underwent subtotal resection and fractionated stereotactic radiosurgery were alive and well with residual tumor at the time of the last follow-up. However, the majority of patients were followed up for a relatively short period of time, and the recurrence rate may increase after longer term follow-up. CM is an uncommon type of meningioma that primarily occurs in adults, and lack sex predilection. Hematological abnormalities or other systemic manifestations are sometimes observed, especially in younger patients. As a WHO grade II subtype, CM has a high rate of recurrence and need to be long-term closely followed-up. A gross total resection is the first choice. Postoperative radiotherapy is also recommended, especially if the tumor is invasive or recurrent, or total resection is not possible.